Field and depot maintenance manual : magneto, ignition, assembly, 2920-529-8247, 2920-740-3411, 2920-737-2995, and 2920-753-9854 (Bendix-Scintilla types S4LN-32 and S6LN-32), end item application, engine, gasoline, 4-cylinder, continental model AOI-268-3A and -3B (TM 9-7605-1) ....

"June 1960."

Field and depot maintenance manual : engine, gasoline, "V" type, air cooled, 12-cylinder, fuel injected, supercharged, -2805-695-6237, (Continental model AVSI-1790-6) and fuel injected, (unsupercharged), -2805-293-9662, (Continental model AVI-1790-8) : end item application, tank, combat, full tracked, 90-mm, M48A2, (TM 9-2350-208) ....

Includes index.

Field and depot maintenance manual : engine, gasoline, fuel injected, supercharged, horizontal-opposed, air cooled, six cylinder, assembly-2805-528-6015, (Continental model AOSI-895-5 and AOSI-895-5M) : end item application : gun, self-propelled, full tracked, twin 40-mm, M42A1 (TM 9-2350-202), howitzer, self-propelled, full tracked, 105-mm, M52A1 (TM 9-2350-209) ....

Includes index.

Field and depot maintenance for engine, diesel (multifuel), turbosupercharged, fuel injected, water cooled, 6-cylinder, assembly-2815-897-5061, (Continental model LDS-427-2) and clutch, assembly (ORD 7748995), (Long model 13CF) : end item application, truck, cargo, 2 1/2 ton, 6 x 6, M35A1, (multifuel)--(TM 9-2320-235).

"February 1964."

Field and depot maintenance manual for pump, injector, fuel assembly, 2910-333-5006 (Simmonds model SU-15G3), pump, injector, fuel assembly, 2910-571-6766 (Simmonds model SU-570) ... end item application, engine, gasoline, 6-cylinder, Continental model AOI-402-5 (TM 9-2805-210) ....

Includes index.

Unit maintenance repair parts and special tools lists : crane, truck mounted hydraulic, 25 ton (CCE), NSN 3810-01-054-9779, Grove model TM S-300-5.

Includes indexes.

Intermediate direct support and intermediate general support maintenance repair parts and special tools list : crane, truck mounted, hydraulic, 25 ton (CCE), 3810-01-054-9779, Grove model TM S-300-5.

"January 1989."

Operator, organizational, and direct support maintenance manual : air conditioner, base mounted, air cooled, electric motor driven, 120/208 volts, 3 phase, 50/60 cycle, 5 stack configuration (Thermo King model S18-104 TM 5) FSN 4120-926-1203, (Keco model F18000-6) FSN 4120-168-2044, (Mecom model 19099-G 18000-5-MEC) FSN 4120-406-3222.

Includes index.

Organizational, direct and general support repair parts and special tools list for air conditioner, vertical, compact, 9,000 BTU/hr, 208 volts, 3-phase, 50/60 Hz, (Tiernay model TM-9KV-208-3-60), NSN 4120-01-091-9672.

Includes index.

Barometers, ML-102-B, ML-102-D, ML-102-E, ML-102-F, and ML-316/TM.

"November 1944."

Hydrogen generator ML-303/TM and hydrogen generator set AN/TMQ-3.

"August 1956."

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX (TM) adjuvant in women with cervical intraepithelial neoplasia

Purpose: Persistent infection of cervical epithelium with high risk human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV 16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX(TM) adjuvant (HPV16 Immunotherapeutic) for patients with CIN. Experimental design: Patients with CIN (n = 3 1) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy. Results: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients. Conclusions : The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX(TM) adjuvant is safe and induces vaccine antigen specific cell mediated immunity. (C) 2004 Elsevier Ltd. All rights reserved.

An in vitro study of the anti-microbial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream Silvazine (TM), 1% silver sulphadiazine cream Flamazine (TM) and a silver coated dressing Acticoat (TM)

Burn sepsis is a leading cause of mortality and morbidity in patients with major burns. The use of topical anti-microbial agents has helped improve the survival in these patients. There are a number of anti-microbials available, one of which, Silvazine(TM) (1% silver sulphadiazine (SSD) and 0.2% chlorhexidine digluconate), is used only in Australasia. No study, in vitro or clinical, had compared Silvazine(TM) with the new dressing Acticoat(TM). This study compared the anti-microbial activity of Silvazine(TM), Acticoa(TM) and 1% silver sulphadiazine (Flamazine(TM)) against eight common burn wound pathogens. Methods: Each organism was prepared as a suspension. A 10 mul inoculum of the chosen bacterial isolate (representing approximately between 104 and 105 total bacteria) was added to each of four vials, followed by samples of each dressing and a control. The broths were then incubated and 10 mul loops removed at specified intervals and transferred onto Horse Blood Agar. These plates were then incubated for 18 hours and a colony count was performed. Results: The data demonstrates that the combination of 1% SSD and 0.2% chlorhexidine digluconate (Silvazine(TM)) results in the most effective killing of all bacteria. SSD and Acticoat(TM) had similar efficacies against a number of isolates, but Acticoat(TM) seemed only bacteriostatic against E. faecalis and methicillin-resistant Staphylococcus aureus. Viable quantities of Enterobacter cloacae and Proteus mirabilis rei named at 24 h. Conclusion: The combination of 1% SSD and 0.2% chlorhexidine digluconate (Silvazine(TM)) is a more effective anti-microbial against a number of burn wound pathogens in this in vitro study. A clinical study of its in vivo anti-microbial efficacy is required. (C) 2003 Elsevier Ltd and ISBI. All rights reserved.

Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1)

Multidrug resistance protein 1 (MRP1) confers drug resistance and also mediates cellular efflux of many organic anions. MRP1 also transports glutathione (GSH); furthermore, this tripeptide stimulates transport of several substrates, including estrone 3-sulfate. We have previously shown that mutations of Lys(332) in transmembrane helix (TM) 6 and Trp(1246) in TM17 cause different substrate-selective losses in MRP1 transport activity. Here we have extended our characterization of mutants K332L and W1246C to further define the different roles these two residues play in determining the substrate and inhibitor specificity of MRP1. Thus, we have shown that TM17-Trp(1246) is crucial for conferring drug resistance and for binding and transport of methotrexate, estradiol glucuronide, and estrone 3-sulfate, as well as for binding of the tricyclic isoxazole inhibitor N-[3-(9-chloro-3-methyl-4-oxo-4H-isoxazolo-[4,3-c]quinolin-5-yl)-cyclohexylmethyl]-benzamide (LY465803). In contrast, TM6-Lys(332) is important for enabling GSH and GSH-containing compounds to serve as substrates (e.g., leukotriene C(4)) or modulators (e.g., S-decyl-GSH, GSH disulfide) of MRP1 and, further, for enabling GSH (or S-methyl-GSH) to enhance the transport of estrone 3-sulfate and increase the inhibitory potency of LY465803. On the other hand, both mutants are as sensitive as wild-type MRP1 to the non-GSH-containing inhibitors (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid (MK571), 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]-ethanone (LY171883), and highly potent 6-[4'-carboxyphenylthio]-5[S]-hydroxy-7[E], 11[Z]14[Z]-eicosatetrenoic acid (BAY u9773). Finally, the differing abilities of the cysteinyl leukotriene derivatives leukotriene C(4), D(4), and F(4) to inhibit estradiol glucuronide transport by wild-type and K332L mutant MRP1 provide further evidence that TM6-Lys(332) is involved in the recognition of the gamma-Glu portion of substrates and modulators containing GSH or GSH-like moieties.